---
title: "Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274836033.md"
description: "Eikon Therapeutics, Inc is set to IPO on February 5, 2026, on NASDAQ under the ticker EIKN. The shares are expected to be priced between $16.00 and $18.00 each, with a 180-day insider lock-up period ending on August 4, 2026. The company focuses on developing innovative medicines for serious unmet medical needs."
datetime: "2026-02-04T15:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274836033.md)
  - [en](https://longbridge.com/en/news/274836033.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274836033.md)
---

# Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow

**Eikon Therapeutics, Inc** (NASDAQ:EIKN) IPO will take place February, 05 on the NASDAQ exchange under the ticker EIKN.

The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on August 04, 2026.

**See also:** **Benzinga IPO Calendar**

### About Eikon Therapeutics, Inc

Eikon Therapeutics, Inc is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs.

**See also:** **Benzinga's Most Shorted Stocks**

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ANIK.US](https://longbridge.com/en/quote/ANIK.US.md)
- [NBSE.ESC.US](https://longbridge.com/en/quote/NBSE.ESC.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Anika Reports First Quarter 2026 Financial Results | ANIK Stock News](https://longbridge.com/en/news/284554290.md)
- [Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches](https://longbridge.com/en/news/285037962.md)
- [Major Investor Makes Bold New Move on Seaport Therapeutics Stock](https://longbridge.com/en/news/285144653.md)
- [Anika Therapeutics Q1 revenue rises 13%](https://longbridge.com/en/news/284558115.md)
- [Anika Therapeutics Signals Momentum Amid Regulatory Hurdles](https://longbridge.com/en/news/284671913.md)